|
6A.1 Which one of the following could best suit as the name for the Hyperthermic intraperitoneal chemotherapy?
(just one alternative allowed)
|
Hyperthermic intraperitoneal chemotherapy (HIPEC);[1]
First round: 61,29 % - Second round: 78,13 % |
|
Intraperitoneal hyperthermic perfusion (IPHP);[2]
First round: 3,23 % - Second round: 0 % |
|
Hyperthermic intraperitoneal intraoperative chemotherapy (HIIC);[3]
First round: 22,58 % - Second round: 12,50 % |
|
Intraperitoneal hyperthermic chemoperfusion (IPHC);[4]
First round: 6,45 % - Second round: 3,13 % |
|
Intraoperative chemohyperthermic peritoneal perfusion (CHPP);[5]
First round: 0 % - Second round: 0 % |
|
Hyperthermic antiblastic peritoneal perfusion (HAPP);[6]
First round: 0 % - Second round: 0 % |
|
Intraperitoneal chemohyperthermia;[7]
First round: 6,45 % - Second round: 6,25 % |
6A.2 In the performance of hyperthermic intraperitoneal chemotherapy which one the following techniques could be the best option to assure a better drug and heat distribution, less morbidity, a better treatment outcome and safety for the operating theatre personnel?
(just one alternative allowed)
|
Open abdominal technique;[8]
First round: 25,81 % - Second round: 25,00 % |
|
Peritoneal cavity expander;[9]
First round: 3,23 % - |
|
Closed abdominal technique;(4,26)
First round: 9,68 % - Second round: 6,25 % |
|
Semi-opened technique;(30)
First round: 0 % - Second round: 3,13 % |
|
There is no sufficient evidence in literature confirming the superiority of one technique over the others in terms of outcome, morbidity and safety to the personnel of the operating theatre. Each option has its own operational advantages and disadvantages and future prospective studies must be conducted to establish which one is the best alternative.
First round: 61,29 % - Second round: 62,50 % |
| [1] Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol. 2004 Feb;85(2):61-7. |
| [2] Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C, Kusamura S. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004 Apr;11(4):393-8. |
| [3] Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, Cavaliere F, Kusamura S, Gronchi A, Lise M. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer. 2004 May 1;100(9):1943-50 |
| [4] Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999 Feb 1;85(3):529-34. |
| [5] Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg. 2005 Mar;92(3):370-5. |
| [6] De Simone M, Barone R, Vaira M, Aghemo B, Mioli P, Franco C, Scuderi S, Costamagna D, Dei Poli M. Semi-closed hyperthermic-antiblastic peritoneal perfusion (HAPP) in the treatment of peritoneal carcinosis. J Surg Oncol. 2003 Feb;82(2):138-40. No abstract available. |
| [7] Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg. 2004 Jun;91(6):747-54. |
| [8] Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999 Dec;6(8):790-6 |
| [9] Fujimura T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, Sugiyama K, Hasegawa H, Katayama K, Miwa K, et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer. 1990 Jan 1;65(1):65-71 |
|
